-cept
A receptor fusion protein: part of a receptor joined to an antibody's Fc region, soaking up the signal the receptor would bind.
- Drugs ending in -cept: 40
- Approved somewhere: 9
- With a US drug page: 6
Approved and clinical-stage drugs in ChEMBL whose names ending in -cept or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Atacicept | Phase 3 | TNFSF13B, TNFSF13 | Tumor necrosis factor ligand superfamily member 13B inhibitor |
| Tilmanocept | Approved | — | Diagnostic agent |
| Batiraxcept | Phase 3 | GAS6 | Growth arrest-specific protein 6 inhibitor |
| Goflikicept | Phase 3 | — | — |
| Telitacicept | Phase 3 | — | — |
| Evorpacept | Phase 2 | CD47 | Leukocyte surface antigen CD47 inhibitor |
| Lesigercept | Phase 2 | — | — |
| Maplirpacept | Phase 2 | — | — |
| Ontorpacept | Phase 2 | — | — |
| Recifercept | Phase 2 | — | — |
| Timdarpacept | Phase 2 | — | — |
| Valziflocept | Phase 2 | — | — |
| Acazicolcept | Phase 1 | — | — |
| Davoceticept | Phase 1 | — | — |
| Inbakicept | Phase 1 | — | — |
| Ipafricept | Phase 1 | FZD8 | Frizzled-8 antagonist |
| Povetacicept | Phase 1 | — | — |
| Briobacept | — | TNFSF13B | Tumor necrosis factor ligand superfamily member 13B inhibitor |
| Aflibercept | Approved | VEGFA, PGF | Vascular endothelial growth factor A inhibitor |
| Conbercept | Phase 3 | VEGFA, VEGFB, PGF, VEGFC | Vascular endothelial growth factor A inhibitor |
| Sozinibercept | Phase 3 | — | — |
| Mirococept | — | CR1 | Complement receptor type 1 inhibitor |
| Alefacept | Approved | CD2 | T-cell surface antigen CD2 inhibitor |
| Rilonacept | Approved | IL1B | Interleukin-1 beta inhibitor |
| Etanercept | Approved | TNF | TNF-alpha inhibitor |
| Asunercept | Phase 3 | FASLG | Tumor necrosis factor ligand superfamily member 6 binding agent |
| Onercept | Phase 3 | TNF | TNF-alpha inhibitor |
| Tanfanercept | Phase 3 | — | — |
| Baminercept | Phase 2 | LTA, LTB, TNFSF14 | Heterotrimeric lymphotoxin LTa1b2 inhibitor |
| Pegsunercept | Phase 2 | TNF | TNF-alpha inhibitor |
| Lenercept | — | TNF | TNF-alpha inhibitor |
| Opinercept | — | — | — |
| Abatacept | Approved | CD86, CD80 | T-lymphocyte activation antigen CD86 inhibitor |
| Belatacept | Approved | CD86, CD80 | T-lymphocyte activation antigen CD86 inhibitor |
| Luspatercept | Approved | Transforming growth factor beta | Transforming growth factor beta inhibitor |
| Sotatercept | Approved | INHBA | Inhibin beta A chain inhibitor |
| Dalantercept | Phase 3 | GDF2, BMP10 | Growth/differentiation factor 2 inhibitor |
| Ramatercept | Phase 2 | MSTN | Growth/differentiation factor 8 inhibitor |
| Elritercept | Phase 1 | — | — |
| Alvircept sudotox | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO